Business Context and Reporting Period
This Form 8-K filing by Amphastar Pharmaceuticals, Inc. (Nasdaq: AMPH) reports on events occurring on March 3, 2026. The filing details the execution of new executive employment agreements with two senior officers: Jacob Liawatidewi (Executive Vice President of Corporate Administration Center, Secretary, and Board Member) and Rong Zhou (Senior Executive Vice President of Production Center).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
- Liawatidewi Base Salary: $525,800 annually.
- Liawatidewi Target Bonus: 55% of base salary.
- Zhou Base Salary: $590,000 annually.
- Zhou Target Bonus: 53% of base salary.
Material Changes
The material change reported is the formalization of compensation and severance terms for the named executives, effective March 3, 2026. Key terms include:
- Term: Initial one-year term with automatic annual renewals unless 90 days' notice of non-renewal is provided.
- Severance (Qualifying Termination): Upon termination without cause, non-renewal, or resignation for "good reason," executives receive a lump sum equal to 2x the sum of their highest annual base salary (prior 12 months) plus their average annual bonus (prior 2 fiscal years).
- Benefits Continuation: Up to 12 months of health insurance premium payments following a qualifying termination.
- Equity Acceleration: 100% acceleration of unvested equity awards upon qualifying termination or change in control.
- Change in Control: Triggers 100% equity acceleration immediately prior to the event. If a qualifying termination occurs within one year of a change in control, severance includes an additional 12-month extension of health benefits.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or management commentary regarding business operations. The primary risk disclosed relates to the potential financial impact of the severance provisions, specifically the "golden parachute" payments subject to Section 280G of the Internal Revenue Code. The agreements include a "gross-up" or "best after-tax" provision to ensure executives receive the maximum after-tax benefit if excise taxes apply.
Investor Verification Checklist
- Verify the total potential severance liability by calculating the 2x multiplier against the executives' most recent actual bonus figures (not provided in this text).
- Review the definitions of "good reason" and "cause" in the full Employment Agreements (Exhibit 10.1) to understand the triggers for severance.
- Assess the impact of the 100% equity acceleration clause on the company's dilution and compensation expense in the event of a change in control.
- Confirm the status of the executives' prior compensation arrangements to determine if these agreements represent a significant increase in total compensation.